Globus Medical (GMED) Stock Forecast & Price Target

$84.97 +1.38 (+1.65%)

(As of 11/21/2024 ET)

Globus Medical - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
1

Hold
3

Buy
8

Based on 12 Wall Street analysts who have issued ratings for Globus Medical in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a sell rating, 3 have given a hold rating, and 8 have given a buy rating for GMED.

Consensus Price Target

$88.18
3.78% Upside

According to the 12 analysts' twelve-month price targets for Globus Medical, the average price target is $88.18. The highest price target for GMED is $100.00, while the lowest price target for GMED is $78.00. The average price target represents a forecasted upside of 3.78% from the current price of $84.97.

Get the Latest News and Ratings for GMED and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Globus Medical and its competitors.

GMED Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)	4 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	7 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$88.18	$77.78	$77.00	$65.11
Forecasted Upside	3.78% Upside	6.02% Upside	6.87% Upside	41.64% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

GMED Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GMED Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Globus Medical Stock vs. The Competition

Type	Globus Medical	Medical Companies	S&P 500
Consensus Rating Score	2.58	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	3.78% Upside	26,677.72% Upside	8.51% Upside
News Sentiment Rating	Positive News See Recent GMED News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	Morgan Stanley 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$74.00 ➝ $83.00	+2.62%
11/6/2024	Roth Mkm 1 of 5 stars		Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00	+23.38%
11/6/2024	Canaccord Genuity Group 1 of 5 stars		Boost Target	Buy ➝ Buy	$79.00 ➝ $85.00	+4.87%
11/6/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$80.00 ➝ $92.00	+13.51%
11/6/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$80.00 ➝ $92.00	+13.12%
11/6/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	V. Chopra Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$78.00 ➝ $88.00	+8.92%
This Bull Market Indicator called NVDA at $116 (Ad) Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here
11/6/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. O'brien Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$80.00 ➝ $100.00	+32.29%
11/6/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
11/6/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underperform ➝ Underperform	$55.00 ➝ $80.00	+5.83%
10/14/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$77.00 ➝ $78.00	+10.03%
8/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$85.00 ➝ $93.00	+26.00%
8/7/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$78.00 ➝ $79.00	+14.48%
2/10/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$90.00 ➝ $70.00	+11.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:55 AM ET.

GMED Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Globus Medical is $88.18, with a high forecast of $100.00 and a low forecast of $78.00.
: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There is currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GMED shares.
: According to analysts, Globus Medical's stock has a predicted upside of 3.78% based on their 12-month stock forecasts.
: Globus Medical has been rated by research analysts at Bank of America, BTIG Research, Canaccord Genuity Group, Morgan Stanley, Needham & Company LLC, Piper Sandler, Roth Mkm, Royal Bank of Canada, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.
: Analysts like Globus Medical less than other "medical" companies. The consensus rating score for Globus Medical is 2.58 while the average consensus rating score for "medical" companies is 2.80. Learn more on how GMED compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

This page (NYSE:GMED) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Globus Medical (GMED) Stock Forecast & Price Target